Global X Genomics & Biotechnology UCITS ETF (LON:GNOG)
London · Delayed Price · Currency is GBP · Price in GBX 4.891
+0.097 (2.01%)
Aug 22, 2025, 4:35 PM BST
2.01% (1Y)
| Assets | 7.80M |
| Expense Ratio | 0.60% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -21.75% |
| Volume | 1,063 |
| Open | 4.846 |
| Previous Close | 4.794 |
| Day's Range | 4.834 - 4.914 |
| 52-Week Low | 3.680 |
| 52-Week High | 6.270 |
| Beta | 1.06 |
| Holdings | 49 |
| Inception Date | Nov 2, 2021 |
About GNOG
The Funds investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index
Asset Class Equity
Category Theme
Stock Exchange London Stock Exchange
Ticker Symbol GNOG
Provider Global X
Index Tracked Solactive Genomics v2 Index - Benchmark TR Net
Performance
GNOG had a total return of -21.75% in the past year, including dividends. Since the fund's inception, the average annual return has been -26.06%.
Top 10 Holdings
46.63% of assets| Name | Symbol | Weight |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | ALNY | 6.96% |
| Avidity Biosciences, Inc. | RNA | 5.30% |
| CRISPR Therapeutics AG | CRSP | 5.07% |
| Illumina, Inc. | ILMN | 4.85% |
| Guardant Health, Inc. | GH | 4.70% |
| Qiagen N.V. | QGEN | 4.27% |
| Bio-Techne Corporation | TECH | 3.97% |
| Natera, Inc. | NTRA | 3.97% |
| Legend Biotech Corporation | LEGN | 3.81% |
| Moderna, Inc. | MRNA | 3.72% |